<DOC>
	<DOCNO>NCT02452775</DOCNO>
	<brief_summary>This randomize pilot trial test addition 2 investigational agent , Montanide poly-ICLC ( TLR3 agonist ) backbone autologous oxidized tumor cell lysate vaccine ( OC-L ) administer GMCSF subject primary epithelial ovarian , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>Autologous OC-L Vaccine Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<criteria>1 . Subject primary ovarian ( include low malignant potential ) , fallopian tube , primary peritoneal cancer FIGO stage III IV define surgically completion initial abdominal surgery . 2 . Subject cytoreductive surgery complete first line platinum base chemotherapy adjuvant neoadjuvant set part standard care treatment . 3 . Subject evidence disease base radiographical image 4 . Subject appropriate tissue available cytoreductive surgery tumor lysate preparation . 5 . Lysate must meet release criterion . 6 . Subject 18 year age old . 7 . Subject ECOG performance status ≤ 2 . 8 . Subject understood sign study specific inform consent . 9 . Subjects screen 1 12 week last cycle chemotherapy . 10 . Subjects screen time complete last cycle chemotherapy till progression first recurrence disease . 11 . Subject least 4 week postoperative recovery surgery prior enrollment ensure complete wound healing . 12 . Subjects screen fails reenrolled causation screen fail correct . 1 . Subject tumor lysate meet release criterion 2 . Subject positive serum Yo antibody ( Does need repeat performed past ) 3 . Subject chronic acute hepatitis C infection . Subject old infection clear may include . 4 . Subject chronic acute hepatitis B infection . Subject old infection clear may include . 5 . Subject positive test result screen visit one following : 1 . HTLV1/2 2 . AntiHIV 1 Antibody ( αHIV1 ) 6 . Subject require likely require twoweek course corticosteroid intercurrent illness . Subject must complete course corticosteroid 2 week screen meet eligibility . 7 . Subject renal insufficiency define serum creatinine &gt; 2.2 mg/dl BUN &gt; 40 mg/dl . Note : If creatinine great 1.5 x ULN , creatinine clearance must great 60ml/min . 8 . Subject proteinuria &gt; 3.5 gm 24 hr eligible study 9 . Subject liver failure define serum total bilirubin &gt; 2.0 and/or serum transaminases &gt; 3X upper limit normal . 10 . Subject hematopoietic failure baseline define one following : 1 . Platelets &lt; 100,000/ mm3 2 . WBC &lt; 2,500/mm3 3 . Absolute Neutrophil Count ( ANC ) &lt; 1,000/mm3 4 . Absolute lymphocyte count &lt; 200/ mm3 5 . Hematocrit &lt; 30 % 11 . Subject acute infection require specific therapy . Acute therapy must complete within seven day prior study enrollment . 12 . Subject serious , nonhealing wound , ulcer , bone fracture . 13 . Subject clinically significant cardiovascular disease include : 1 . Uncontrolled hypertension ; 2 . Myocardial infarction unstable angina within 6 month prior enrollment 3 . New York Heart Association ( NYHA ) Grade II great congestive heart failure 14 . Subject grade II great peripheral vascular disease . 15 . Subject clinically significant peripheral artery disease , e.g. , claudication , within 6 month . 16 . Subject underlying condition , would contraindicate therapy study treatment 17 . Subject organ allograft . 18 . Subject receive medication ( ) might affect immune function . Use H2 antagonist prohibit antihistamine five day five day injection study vaccine . However , NSAIDS include COX2 inhibitor , acetaminophen aspirin permit .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>